A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings

MLA

John K. Botson, et al. “A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings.” ACR Open Rheumatology, vol. 5, no. 8, Aug. 2023, pp. 407–18. EBSCOhost, https://doi.org/10.1002/acr2.11578.

APA

John K. Botson, Kenneth Saag, Jeff Peterson, Katie Obermeyer, Yan Xin, Brian LaMoreaux, Lissa Padnick‐Silver, Supra Verma, Suneet Grewal, Amar Majjhoo, John R. P. Tesser, & Michael E. Weinblatt. (2023). A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings. ACR Open Rheumatology, 5(8), 407–418. https://doi.org/10.1002/acr2.11578

Chicago

John K. Botson, Kenneth Saag, Jeff Peterson, Katie Obermeyer, Yan Xin, Brian LaMoreaux, Lissa Padnick‐Silver, et al. 2023. “A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings.” ACR Open Rheumatology 5 (8): 407–18. doi:10.1002/acr2.11578.